DDIT3 and diffuse large B-cell lymphoma: This corresponds well to the recently published high survival rates in a cohort of 18 primary OA-DLBCL-NOS patients treated with R-CHOP [37], and limited-stage DLBCL-NOS in general treated with R-CHOP [38].